GHDX : Summary for Genomic Health, Inc. - Yahoo Finance

U.S. Markets open in 5 hrs 16 mins

Genomic Health, Inc. (GHDX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
28.80-0.31 (-1.06%)
At close: 4:00PM EST
People also watch
LMNXQGENFMIACORSGEN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close29.11
Open29.10
Bid24.30 x 100
Ask32.00 x 100
Day's Range28.42 - 29.28
52 Week Range22.00 - 33.96
Volume158,428
Avg. Volume133,193
Market Cap964.2M
Beta0.45
PE Ratio (TTM)-52.65
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Genomic Health, Inc. breached its 50 day moving average in a Bullish Manner : GHDX-US : February 21, 2017
    Capital Cube21 hours ago

    Genomic Health, Inc. breached its 50 day moving average in a Bullish Manner : GHDX-US : February 21, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Genomic Health, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • Genomic Health, Inc. :GHDX-US: Earnings Analysis: Q4, 2016 By the Numbers : February 16, 2017
    Capital Cube6 days ago

    Genomic Health, Inc. :GHDX-US: Earnings Analysis: Q4, 2016 By the Numbers : February 16, 2017

    Categories: Yahoo Finance Get free summary analysis Genomic Health, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Genomic Health, Inc. – Quest Diagnostics Incorporated, Myriad Genetics, Inc. and QIAGEN NV (DGX-US, MYGN-US and QGEN-US) that have also reported for this period. Highlights Summary numbers: Revenues ... Read more (Read more...)

  • PR Newswire6 days ago

    Four New Studies of Oncotype DX® Genomic Prostate Score™ (GPS) Reconfirm Value of Test in Guiding Early-stage Prostate Cancer Risk Assessment and Treatment Selection

    Collectively, these new data highlight the test's ability to predict disease aggressiveness and refine risk stratification across National Comprehensive Cancer Network (NCCN) clinical risk groups. "We now have 22 clinical studies, involving more than 4,200 prostate cancer patients, that distinguish Oncotype DX as the only test developed specifically for men who are deciding between active surveillance or definitive treatment. The test is validated to provide individualized information about both the current state and future risk of patients' prostate cancer," said Phil Febbo, M.D., chief medical officer, Genomic Health.